Online Only Articles

Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma

Department of Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada;Dalla Lana School of Public Health, University of Toronto, ON, Canada
Division of Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada;Department of Lymphoid Cancer Research, BC Cancer Agency, Vancouver, BC, Canada
Department of Pathology, BC Cancer Agency, Vancouver, BC, Canada;Department of Lymphoid Cancer Research, BC Cancer Agency, Vancouver, BC, Canada
Department of Lymphoid Cancer Research, BC Cancer Agency, Vancouver, BC, Canada
Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada
Department of Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada
Department of Pathology, BC Cancer Agency, Vancouver, BC, Canada;Department of Lymphoid Cancer Research, BC Cancer Agency, Vancouver, BC, Canada
Department of Pathology, Royal Jubilee Hospital, Victoria, BC, Canada
Dalla Lana School of Public Health, University of Toronto, ON, Canada
Division of Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada;Department of Lymphoid Cancer Research, BC Cancer Agency, Vancouver, BC, Canada
Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada;Department of Pathology, Royal Jubilee Hospital, Victoria, BC, Canada;Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada
Department of Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada;School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Vol. 102 No. 5 (2017): May, 2017 https://doi.org/10.3324/haematol.2016.159087